share_log

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

Pulse Biosciences宣佈更新的供股時間,最高可達6000萬美元
Pulse Biosciences ·  05/20 12:00

HAYWARD, Calif.--(BUSINESS WIRE)--May 20, 2024-- Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology, today announced that the Company's Board of Directors has determined a new record date for the Company's previously announced rights offering (the "Rights Offering"), which will be available to all holders of record of the Company's common stock, par value $0.001 per share (the "Common Stock"), now as of the close of the market on Friday, May 31, 2024 (the "Record Date"). This new record date was changed from the original record date of May 16, 2024.

加利福尼亞州海沃德--(美國商業資訊)--2024年5月20日--Pulse Biosciences, Inc.(納斯達克股票代碼:PLSE)(“Pulse” 或 “公司”)是一家利用其新型專有CellFx納秒脈衝場消融(NSPFA)技術的公司,今天宣佈,公司董事會已經確定了公司先前宣佈的供股(“供股”)的新紀錄日期,該發行(“供股”)截至2024年5月31日星期五收盤時,公司普通股(每股面值0.001美元)的所有登記持有人(“普通股”)(”記錄日期”).這個新記錄日期已從 2024 年 5 月 16 日的原始記錄日期更改。

The Company intends to distribute to all holders of Common Stock as of the Record Date non-transferable subscription rights to purchase up to an aggregate of 6,000,000 units ("Units") at a price per Unit equal to the lesser of: (i) $10 (the "Initial Price") and (ii) the volume weighted average price of the Common Stock for the ten trading day period through and including the expiration date of the Rights Offering, now contemplated to be Wednesday, June 26, 2024 (the "Alternate Price"). Only persons who own Company stock on the May 31, 2024 Record Date will be able to participate in the Rights Offering. Assuming that the Rights Offering is fully subscribed, the Company will receive gross proceeds of $60,000,000, less expenses related to the Rights Offering. As indicated below, please refer to the Registration Statement on Form S-3, as amended, for more complete information regarding the planned Rights Offering.

公司打算向截至記錄日的所有普通股持有人分配不可轉讓的認購權,以每單位價格購買總計不超過6,000,000個單位(“單位”)的認購權:(i)10美元(“初始價格”)和(ii)截至供股到期日(現計劃爲星期三)的十個交易日期間普通股的交易量加權平均價格,2024 年 6 月 26 日(“替代價格”)。只有在2024年5月31日記錄日擁有公司股票的人才能參與供股。假設本次供股獲得全額認購,公司將獲得6000萬美元的總收益,減去與供股相關的費用。如下所示,請參閱經修訂的S-3表格上的註冊聲明,以獲取有關計劃中的供股的更多完整信息。

Each stockholder will receive one subscription right entitling the holder to purchase a fraction of a Unit for each share of Common Stock owned at 5:00 p.m., Eastern Time, on the Record Date. Each Unit shall consist of one share of Common Stock and two warrants, each being a warrant to purchase one-half of one share of Common Stock at an exercise price per whole share that shall be equal to 110% of the per-Unit subscription price (provided, that, the aggregate number of shares of Common Stock that shall be issuable upon the exercise of each set of warrants included in a given subscription for Units shall be rounded up to the nearest whole share). Each warrant will be exercisable immediately upon completion of the Rights Offering and will expire on the fifth anniversary of the completion of the Rights Offering. The respective warrants will be subject to redemption by the Company for $0.01 per underlying share of Common Stock, on not less than thirty (30) days' written notice, if the volume weighted average price of our Common Stock equals or exceeds: (i) in respect of one such warrant, 150% of the exercise price for the warrants, subject to adjustment, per whole share, for twenty (20) consecutive trading days, and (ii) in respect of the other such warrant, 200% of the exercise price for the warrants, subject to adjustment, per whole share, for twenty (20) consecutive trading days, provided that, in each case, the Company may not redeem the warrants prior to the date that is three months after the issuance date. To the extent that the Alternate Price is lower than the Initial Price, the Company will sell additional Units, but will not sell fractional Units.

每位股東將獲得一項認購權,使持有人有權在記錄日美國東部時間下午 5:00 爲每股普通股購買一小部分股份。每個單位應由一股普通股和兩份認股權證組成,每份認股權證是以每股行使價購買一半普通股的認股權證,行使價等於每單位認購價格的110%(前提是,行使給定單位認購中包含的每套認股權證時可發行的普通股總數應四捨五入至最接近的整股)。每份認股權證將在供股完成後立即行使,並將在供股完成五週年之際到期。如果我們的普通股成交量加權平均價格等於或超過:(i)就一份此類認股權證而言,連續二十(20)個交易日爲認股權證行使價的150%,則公司將在不少於三十(30)天書面通知的情況下以每股普通股0.01美元的價格贖回相應的認股權證,並且(ii)其他此類認股權證,爲認股權證行使價的200%,連續二十(20)股每股調整後每股權證交易日,前提是,在每種情況下,公司都不得在發行日期後三個月之前贖回認股權證。如果替代價格低於初始價格,公司將出售更多單位,但不會出售部分單位。

The Rights Offering will include an over-subscription right to permit each rights holder that exercises its basic subscription rights in full to purchase additional Units that remain unsubscribed at the expiration of the offering, but the Company will not sell fractional Units. The availability of this over-subscription right will be subject to certain terms and conditions to be set forth in the offering documents.

本次供股將包括超額認購權,允許每位完全行使基本認購權的權利持有人購買在發行到期時仍未認購的額外單位,但公司不會出售部分單位。此超額訂閱權的可用性將受發行文件中規定的某些條款和條件的約束。

Pulse has filed a registration statement (including a prospectus) on Form S-3 with the U.S. Securities and Exchange Commission (the "SEC") on April 3, 2024, as amended on each of April 15, 2024, April 23, 2024, April 25, 2024, and April 30, 2024 (the "Registration Statement"), which is now effective. The Registration Statement covers, among other things, the Rights Offering to which this communication relates. Before you invest, you should read the final prospectus in the Registration Statement, together with any prospectus supplement, that we will file prior to commencing any Rights Offering, and the documents incorporated by reference in the prospectus (or any prospectus supplement), as well as the other documents Pulse has filed with the SEC for more complete information about Pulse and the Rights Offering. You may get these documents for free by visiting EDGAR on the SEC's website at www.sec.gov.

Pulse已於2024年4月3日向美國證券交易委員會(“SEC”)提交了S-3表格的註冊聲明(包括招股說明書),該聲明於2024年4月15日、2024年4月23日、2024年4月25日和2024年4月30日分別進行了修訂(“註冊聲明”),現已生效。除其他外,註冊聲明涵蓋了本通信所涉及的權利發行。在投資之前,您應閱讀註冊聲明中的最終招股說明書以及我們在開始任何供股之前提交的任何招股說明書補充文件,以及招股說明書(或任何招股說明書補充文件)中以引用方式納入的文件,以及Pulse向美國證券交易委員會提交的其他文件,以獲取有關Pulse和供股的更完整信息。您可以通過訪問美國證券交易委員會網站上的EDGAR免費獲得這些文件 www.sec.gov

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

本新聞稿不構成出售要約或徵求購買這些證券的要約,在根據任何此類州或司法管轄區的證券法進行註冊或獲得資格認證之前,在任何州或其他司法管轄區,此類要約、招標或出售爲非法的州或其他司法管轄區也不會出售這些證券。

About Pulse Biosciences

關於脈衝生物科學

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company's proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences是一家致力於健康創新的新型生物電醫學公司,有可能改善患者的生活質量。該公司專有的CellFx nspfa技術向非熱清除細胞提供納秒脈衝的電能,同時保護鄰近的非細胞組織。該公司正在積極開發其CellFx nspfa技術,該技術用於治療心房顫動以及其他一些市場,在這些市場中,該技術可能會對患者和醫療服務提供者的醫療保健產生深遠的積極影響。

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Pulse Biosciences、CellFx、Nano-Pulse 刺激、NPS、Nspfa、CellFx Nspfa 和程式化徽標是脈衝生物科學公司在美國和其他國家的商標和/或註冊商標之一。

Forward-Looking Statements

前瞻性陳述

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company's CellFX nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company's future fundraising efforts and whether those efforts will be successful or allow the Company to continue current operations as planned, statements concerning market opportunities, customer adoption and future use of the CellFX System to address a range of conditions such as atrial fibrillation, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences' current expectations, estimates, and projections regarding Pulse Biosciences' business, operations and other similar or related factors. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expects," "intends," "plans," "projects," "believes," "estimates," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences' control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences' filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

本新聞稿中所有非歷史陳述均爲前瞻性陳述,包括與公司的CellFx nspfa技術和CellFx系統在保留鄰近非細胞組織的同時對細胞進行非熱清除的有效性有關的陳述、有關公司未來籌款活動以及這些努力是否會成功或允許公司按計劃繼續運營的聲明、有關市場機會、客戶採用和未來使用CellFX系統的聲明解決一系列疾病,例如心房顫動和其他未來事件。這些陳述不是歷史事實,而是基於Pulse Biosciences當前對Pulse Biosciences業務、運營和其他類似或相關因素的預期、估計和預測。諸如 “可能”、“將”、“可能”、“應該”、“預期”、“預測”、“潛在”、“繼續”、“期望”、“打算”、“計劃”、“項目”、“相信”、“估計” 等詞語以及其他類似或相關的表述用於識別這些前瞻性陳述,儘管並非所有前瞻性陳述都包含這些詞語。您不應過分依賴前瞻性陳述,因爲前瞻性陳述涉及已知和未知的風險、不確定性以及難以或不可能預測的假設,在某些情況下超出了Pulse Biosciences的控制範圍。由於多種因素,包括Pulse Biosciences向美國證券交易委員會提交的文件中描述的因素,實際業績可能與前瞻性陳述中的結果存在重大差異。即使有新信息可用,Pulse Biosciences也沒有義務修改或更新本新聞稿中的信息以反映未來的事件或情況。

Investor Contacts:
Pulse Biosciences, Inc.
Burke T. Barrett, President and CEO
IR@pulsebiosciences.com

投資者聯繫人:
Pulse Biosciences
伯克·巴雷特,總裁兼首席執行官
IR@pulsebiosciences.com

Or

或者

Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com

吉爾馬丁集團
菲利普·泰勒
415.937.5406
philip@gilmartinir.com

Source: Pulse Biosciences, Inc.

資料來源:Pulse 生物科學公司

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論